MENLO PARK, Calif.,
Nov. 10, 2014 /PRNewswire/ --
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading
biotechnology company in the emerging field of regenerative
medicine, today reported financial results for the third quarter
and nine months ended September 30,
2014.
"Asterias made substantial progress in the third quarter with
respect to our two key development programs that have the potential
to address significant unmet medical needs using our pluripotent
stem cell technology platform," stated Pedro Lichtinger, President and CEO of Asterias.
"We have partnered with leading scientific institutions, and are
poised to initiate a dose-escalation Phase 1/2a clinical trial for
AST-OPC1 in spinal cord injury and to progress AST-VAC2 into a
Phase 1/2a dose-escalation clinical trial in lung cancer in
collaboration with our partner, Cancer Research UK. Regarding our
AST-OPC1 clinical program, we have decided to accelerate the
current timelines by approximately 6 months in order to obtain
safety and efficacy readouts more rapidly. To enable this
acceleration, we plan to double the number of clinical trial sites
and to expand our patient recruitment efforts. In addition, we
intend to seek U.S. Food and Drug Administration (FDA) approval to
increase the robustness of the proof of concept that we will
establish in this Phase 1/2a clinical trial by expanding enrollment
from 13 patients to up to 40 patients. We believe these changes
will increase the statistical confidence of the safety and efficacy
readouts, reduce the risks of the AST-OPC1 program and position the
product for potential accelerated regulatory approvals."
Third Quarter and Recent Events
- Asterias received clearance from the FDA to initiate a
dose-escalation Phase 1/2a clinical trial of AST-OPC1
(oligodendrocyte progenitor cells) in patients with complete
cervical spinal cord injury (SCI). The dose escalation will start
with three patients being dosed 2 million cells and escalate into
two five-patient cohorts at 10 million and 20 million cells,
respectively.
- Asterias signed a Notice of Grant Award (NGA) with the
California Institute of Regenerative Medicine (CIRM). The NGA
provides for the immediate release of clinical development payments
and the release of additional grant funds pursuant to the
previously announced $14.3 million
CIRM grant award for clinical development of AST-OPC1. The grant
provides non-dilutive funding to initiate the Phase 1/2a clinical
trial of AST-OPC1 for complete cervical SCI and other product
development activities for AST-OPC1.
- Asterias, Cancer Research UK (CRUK) and Cancer Research
Technology, the development and commercialization arm of CRUK,
entered into an agreement to advance Asterias' novel immunotherapy
treatment, AST-VAC2, into clinical trials in subjects with
non-small cell lung cancer. Under the agreement, Asterias will
transfer the manufacturing process for AST-VAC2 to CRUK, after
which CRUK will, at its own cost, manufacture clinical grade
AST-VAC2 and conduct the Phase 1/2a clinical trial in the UK,
subject to regulatory approval.
- Successfully distributed 8,000,000 warrants to purchase common
shares of BioTime, Inc. at a purchase price of $5.00 per common share until the warrant expires
on October 1, 2018.
- Simplified the Company's capital structure with the conversion
of all of its outstanding Series B common stock into Series A
common stock. After the automatic conversion of the Series B common
stock, the Series A common stock is now the only outstanding class
of common stock of Asterias.
- Strengthened the Company's Board of Directors by adding
financial expertise and biopharmaceutical leadership experience
with the respective appointments of two additional independent
directors, Andrew Arno and
Natale Ricciardi.
- Asterias Series A common stock commenced trading on the NYSE
MKT under the ticker symbol "AST."
Third Quarter Financial Results
For the three months ended September 30,
2014, total revenue was $84,515, and was comprised of royalty revenues on
product sales by licensees. Operating expenses for the three months
ended September 30, 2014 were
$4.0 million, compared to
$2.7 million in the same period in
2013, and were primarily related to the preparation and
commencement of planned research and development operations.
Research and development expenses in the third quarter 2014 were
$2.6 million, compared to
$1.1 million in the year ago quarter.
Net loss for the three months ended September 30, 2014 was $1.7 million, compared to a net loss of
$2.7 million for the same period in
2013. The reduction in net loss is primarily attributed to the
deferred income tax benefit of approximately $2.3 million that was recorded as of September 30, 2014. There was no deferred income
tax benefit recorded in the three months ended September 30, 2013. On a per share basis, net
loss for the third quarter 2014 was $0.05 per share, compared to $51.62 per share for the year ago quarter. The
decrease in the net loss per share primarily reflects the increased
share count resulting from the issuance of 21.8 million shares of
Asterias Series B common stock to BioTime, Inc. and 6.5 million
shares of Asterias Series A common stock to Geron Corporation under
the previously announced Asset Contribution Agreement that was
executed on October 1, 2013.
Year-to-Date Financial Results
For the nine months ended September 30,
2014, total revenue was $167,207, and was comprised of royalty revenues
on product sales by licensees. Operating expenses for the nine
months ended September 30, 2014 were
$12.0 million, compared to
$4.8 million in the same period in
2013, and were primarily attributed to increased research and
development related activity and increased staffing and operations.
Research and development expenses for the first nine months of 2014
were $7.9 million, compared to
$1.9 million in the year ago period.
General and administrative expenses for the first nine months of
2014 were $4.1 million, compared to
$2.9 million in the year ago period.
Net loss for the nine months ended September
30, 2014 was $6.8 million,
compared to a net loss of $4.8
million for the same period in 2013. The increase in net
loss is offset to some extent by the $5.2
million deferred income tax benefit recorded as of
September 30, 2014. There was no
deferred income tax benefit recorded in the nine months ended
September 30, 2013. On a per share
basis, net loss for the nine months ended September 30, 2014 was $0.22 per share, compared to $93.13 per share for the year ago period. The
decrease in the net loss per share primarily reflects the increased
share count resulting from the issuance of 21.8 million shares of
Asterias Series B common stock to BioTime, Inc. and 6.5 million
shares of Asterias Series A common stock to Geron Corporation under
the previously announced Asset Contribution Agreement that was
completed on October 1, 2013.
Cash and cash equivalents totaled $5.0
million at September 30, 2014,
and the Company held 3,852,880 BioTime common shares, with a market
value of approximately $12.1 million
on that date. For the third quarter, cash burn was $2.8 million. In the fourth quarter, the Company
anticipates a payment from CIRM under the grant award related to
the AST-OPC1 development program. With the CIRM funding, the
Company continues to expect cash burn for the second half of 2014
will total approximately $4.4
million.
Conference Call and Webcast Details
The Company will host a conference call and webcast today,
November 10, 2014, at 4:30 p.m. Eastern / 1:30
p.m. Pacific to discuss the quarter's results and recent
corporate developments.
For both "listen-only" participants and those participants who
wish to participate in the question-and-answer portion of the call,
the dial-in number in the U.S. is 877-407-8291. For participants
outside the U.S., the dial-in number is 201-689-8345. To access the
live webcast, go to http://www.wsw.com/webcast/cc/astb3.
A replay of the conference call will be available for seven
business days beginning about two hours after the conclusion of the
live call. The telephone dial-in number for U.S. participants is
877-660-6853. For participants outside the U.S., the replay dial-in
number is 201-612-7415. To access the replay for all callers, refer
to Conference ID 13594488. An archived webcast will also be
available for 30 days, and may be accessed at
http://www.wsw.com/webcast/cc/astb3.
About Asterias Biotherapeutics
Asterias' core technologies center on stem cells capable of
becoming all of the cell types in the human body, a property called
pluripotency. Asterias plans to develop therapies based on
pluripotent stem cells to treat diseases or injuries in a variety
of medical fields having major unmet needs and without adequate
therapies available. Asterias initial focus is on two clinical
stage programs including oligodendrocyte progenitor cells
(AST-OPC1) for spinal cord injuries and antigen-presenting
allogeneic dendritic cells (AST-VAC2) for lung cancer.
In October 2013, Asterias acquired
the cell therapy assets of Geron Corporation. These assets included
INDs for the clinical stage AST-OPC1 and AST-VAC1 programs, banks
of cGMP-manufactured AST-OPC1 drug product, cGMP master and working
cell banks of human embryonic stem cells, over 400 patents and
patent applications filed worldwide including broad issued claims
to fundamental platform technologies for the scalable growth of
pluripotent stem cells and compositions of matter for several
hESC-derived therapeutic cell types, research cell banks,
customized reagents and equipment, and various assets relating to
the AST-VAC2 program and preclinical programs in cardiology, and
orthopedics.
Asterias is a majority-owned subsidiary of BioTime, Inc., (NYSE
MKT: BTX), a biotechnology company engaged in research and product
development in the field of regenerative medicine. Additional
information about Asterias can be found at
www.asteriasbiotherapeutics.com.
FORWARD-LOOKING STATEMENTS
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Asterias, along with
other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products,
uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the businesses of Asterias,
particularly those mentioned in the cautionary statements found in
Asterias' filings with the Securities and Exchange Commission.
Asterias disclaims any intent or obligation to update these
forward-looking statements
ASTERIAS
BIOTHERAPEUTICS, INC.
|
(a company in the
development stage)
|
|
CONDENSED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
|
(UNAUDITED)
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
September
30,
|
|
|
Nine Months
Ended
September
30,
|
|
|
Period from
Inception
(September 24, 2012)
|
|
|
|
2014
|
|
|
2013
|
|
|
2014
|
|
|
2013
|
|
|
to September 30,
2014
|
|
REVENUE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalties from
product sales
|
|
$
|
84,515
|
|
|
$
|
-
|
|
|
$
|
167,207
|
|
|
$
|
-
|
|
|
$
|
167,207
|
|
Cost of
sales
|
|
|
(42,258)
|
|
|
|
-
|
|
|
|
(83,603)
|
|
|
|
-
|
|
|
|
(83,603)
|
|
Total gross
profit
|
|
|
42,257
|
|
|
|
-
|
|
|
|
83,604
|
|
|
|
-
|
|
|
|
83,604
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EXPENSES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
|
|
(2,568,214)
|
|
|
|
(1,149,059)
|
|
|
|
(7,910,097)
|
|
|
|
(1,931,048)
|
|
|
|
(12,229,592)
|
|
Acquired in-process
research and development
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(17,458,766)
|
|
General and
administrative
|
|
|
(1,468,754)
|
|
|
|
(1,523,732)
|
|
|
|
(4,107,888)
|
|
|
|
(2,888,028)
|
|
|
|
(8,749,636)
|
|
Total operating
expenses
|
|
|
(4,036,968)
|
|
|
|
(2,672,791)
|
|
|
|
(12,017,985)
|
|
|
|
(4,819,076)
|
|
|
|
(38,437,994)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from
operations
|
|
|
(3,994,711)
|
|
|
|
(2,672,791)
|
|
|
|
(11,934,381)
|
|
|
|
(4,819,076)
|
|
|
|
(38,354,390)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER
INCOME/(EXPENSE)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense,
net
|
|
|
(291)
|
|
|
|
-
|
|
|
|
(9,827)
|
|
|
|
-
|
|
|
|
(11,564)
|
|
Gain on sale of fixed
assets
|
|
|
-
|
|
|
|
2,430
|
|
|
|
-
|
|
|
|
2,430
|
|
|
|
2,430
|
|
Other income
(expense), net
|
|
|
26
|
|
|
|
1,833
|
|
|
|
(1,559)
|
|
|
|
1,924
|
|
|
|
(1,575)
|
|
Total other income
(expense), net
|
|
|
(265)
|
|
|
|
4,263
|
|
|
|
(11,386)
|
|
|
|
4,354
|
|
|
|
(10,709)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LOSS BEFORE DEFERRED
INCOME TAX BENEFIT
|
|
|
(3,994,976)
|
|
|
|
(2,668,528)
|
|
|
|
(11,945,767)
|
|
|
|
(4,814,722)
|
|
|
|
(38,365,099)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred income tax
benefit
|
|
|
2,312,693
|
|
|
|
-
|
|
|
|
5,174,977
|
|
|
|
-
|
|
|
|
8,455,672
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET
LOSS
|
|
|
(1,682,283)
|
|
|
|
(2,668,528)
|
|
|
|
(6,770,790)
|
|
|
|
(4,814,722)
|
|
|
|
(29,909,427)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain
(loss) on available-for-sale securities, net
|
|
|
345,549
|
|
|
|
-
|
|
|
|
(108,829)
|
|
|
|
-
|
|
|
|
(3,043,515)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COMPREHENSIVE
LOSS
|
|
$
|
(1,336,734)
|
|
|
$
|
(2,668,528)
|
|
|
$
|
(6,879,619)
|
|
|
$
|
(4,814,722)
|
|
|
$
|
(32,952,942)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net
loss per common share
|
|
$
|
(0.05)
|
|
|
$
|
(51.62)
|
|
|
$
|
(0.22)
|
|
|
$
|
(93.13)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
shares of common stock outstanding — basic and diluted
|
|
|
30,898,819
|
|
|
|
51,700
|
|
|
|
30,659,259
|
|
|
|
51,700
|
|
|
|
|
|
ASTERIAS
BIOTHERAPEUTICS, INC.
|
(a company in the
development stage)
|
|
CONDENSED BALANCE
SHEETS
|
|
|
|
September 30,
2014
(Unaudited)
|
|
|
December
31,
2013
|
|
ASSETS
|
|
|
|
|
|
|
CURRENT
ASSETS
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
5,025,499
|
|
|
$
|
2,171,113
|
|
Available-for-sale
securities, at fair value
|
|
|
12,100,043
|
|
|
|
32,052,217
|
|
BioTime warrants to
be distributed to holders of Series A common stock
|
|
|
7,572,089
|
|
|
|
15,568,307
|
|
Prepaid expenses and
other current assets
|
|
|
352,502
|
|
|
|
340,092
|
|
Total current
assets
|
|
|
25,050,133
|
|
|
|
50,131,729
|
|
|
|
|
|
|
|
|
|
|
NONCURRENT
ASSETS
|
|
|
|
|
|
|
|
|
Intangible assets,
net
|
|
|
26,115,308
|
|
|
|
28,291,584
|
|
Equipment and
furniture, net
|
|
|
1,252,158
|
|
|
|
1,460,518
|
|
Investment in
affiliates
|
|
|
415,543
|
|
|
|
415,543
|
|
Other
assets
|
|
|
360,983
|
|
|
|
54,423
|
|
Total noncurrent
assets
|
|
|
28,143,992
|
|
|
|
30,222,068
|
|
TOTAL
ASSETS
|
|
$
|
53,194,125
|
|
|
$
|
80,353,797
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
CURRENT
LIABILITIES
|
|
|
|
|
|
|
|
|
Obligation to
distribute BioTime warrants to holders of Series A common
stock
|
|
$
|
7,572,089
|
|
|
$
|
15,568,307
|
|
Amount due to
BioTime
|
|
|
406,379
|
|
|
|
2,064,432
|
|
Accounts
payable
|
|
|
386,064
|
|
|
|
567,140
|
|
Accrued
liabilities
|
|
|
140,400
|
|
|
|
95,885
|
|
Total current
liabilities
|
|
|
8,504,932
|
|
|
|
18,295,764
|
|
|
|
|
|
|
|
|
|
|
Long-term
liabilities, net deferred tax liability
|
|
|
10,787,141
|
|
|
|
8,277,548
|
|
TOTAL
LIABILITIES
|
|
|
19,292,073
|
|
|
|
26,573,312
|
|
|
|
|
|
|
|
|
|
|
Commitments and
contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS'
EQUITY
|
|
|
|
|
|
|
|
|
Preferred Stock,
$0.0001 par value, authorized 5,000,000 shares; none issued and
outstanding
|
|
|
-
|
|
|
|
-
|
|
Common Stock, $0.0001
par value, authorized 75,000,000 shares Series A, $0.0001 par
value, and 75,000,000 shares Series B, $0.0001 par value; 6,537,779
shares Series A common stock and 24,361,040 shares Series B common
stock issued and outstanding at September 30, 2014, and 6,537,779
shares Series A common stock and 23,961,040 shares Series B common
stock issued and outstanding at December 31, 2013
|
|
|
3,075
|
|
|
|
3,050
|
|
Additional paid-in
capital
|
|
|
66,851,919
|
|
|
|
79,850,758
|
|
Accumulated other
comprehensive loss on available-for-sale investments
|
|
|
(3,043,515)
|
|
|
|
(2,934,686)
|
|
Deficit accumulated
during the development stage
|
|
|
(29,909,427)
|
|
|
|
(23,138,637)
|
|
Total stockholders'
equity
|
|
|
33,902,052
|
|
|
|
53,780,485
|
|
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
$
|
53,194,125
|
|
|
$
|
80,353,797
|
|
ASTERIAS
BIOTHERAPEUTICS, INC.
|
(a company in the
development stage)
|
|
CONDENSED
STATEMENTS OF CASH FLOWS
|
(UNAUDITED)
|
|
|
|
Nine Months
Ended
September
30,
|
|
|
Period from
inception
(September 24,
2012) to
|
|
|
|
2014
|
|
|
2013
|
|
|
September 30,
2014
|
|
CASH FLOWS FROM
OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(6,770,790)
|
|
|
$
|
(4,814,722)
|
|
|
$
|
(29,909,427)
|
|
Adjustments to
reconcile net loss to net cash provided by/(used in) operating
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquired in-process
research and development
|
|
|
-
|
|
|
|
-
|
|
|
|
17,458,766
|
|
Depreciation
expense
|
|
|
408,613
|
|
|
|
95,244
|
|
|
|
629,208
|
|
Stock-based
compensation
|
|
|
1,400,193
|
|
|
|
441,434
|
|
|
|
2,103,927
|
|
Amortization of
intangible assets
|
|
|
2,176,276
|
|
|
|
-
|
|
|
|
2,901,701
|
|
Gain on sale of
equipment and furniture
|
|
|
-
|
|
|
|
(2,430)
|
|
|
|
(2,430)
|
|
Deferred income tax
benefit
|
|
|
(5,174,977)
|
|
|
|
-
|
|
|
|
(8,455,672)
|
|
Changes in operating
assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Prepaid expenses and
other current assets
|
|
|
(12,410)
|
|
|
|
(220,160)
|
|
|
|
(352,502)
|
|
Accounts
payable
|
|
|
(181,076)
|
|
|
|
353,744
|
|
|
|
386,064
|
|
Accrued
liabilities
|
|
|
44,515
|
|
|
|
234,907
|
|
|
|
140,400
|
|
Amount due to
BioTime
|
|
|
(1,658,053)
|
|
|
|
5,630,991
|
|
|
|
4,005,125
|
|
Net cash (used
in)/provided by operating activities
|
|
|
(9,767,709)
|
|
|
|
1,719,008
|
|
|
|
(11,094,840)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM
INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of equipment
and furniture
|
|
|
(200,253)
|
|
|
|
(1,600,506)
|
|
|
|
(1,446,982)
|
|
Proceeds from sale of
equipment and furniture
|
|
|
-
|
|
|
|
27,500
|
|
|
|
27,500
|
|
Proceeds from sale of
available-for-sale securities
|
|
|
12,660,908
|
|
|
|
-
|
|
|
|
12,660,908
|
|
Payment of security
deposits
|
|
|
(306,560)
|
|
|
|
(54,423)
|
|
|
|
(360,983)
|
|
Net cash provided
by/(used in) investing activities
|
|
|
12,154,095
|
|
|
|
(1,627,429)
|
|
|
|
10,880,443
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM
FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from
issuance of common stock
|
|
|
468,000
|
|
|
|
-
|
|
|
|
5,468,000
|
|
Payment to Geron in
connection with acquisition of assets on October 1, 2013
|
|
|
-
|
|
|
|
-
|
|
|
|
(228,104)
|
|
Net cash provided by
financing activities
|
|
|
468,000
|
|
|
|
-
|
|
|
|
5,239,896
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase in cash
and cash equivalents
|
|
|
2,854,386
|
|
|
|
91,579
|
|
|
|
5,025,499
|
|
Cash and cash
equivalents at beginning of period
|
|
|
2,171,113
|
|
|
|
-
|
|
|
|
-
|
|
Cash and cash
equivalents at end of period
|
|
$
|
5,025,499
|
|
|
$
|
91,579
|
|
|
$
|
5,025,499
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL SCHEDULE
OF NON-CASH FINANCING AND INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of equipment
and furniture, contributed by BioTime
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
(459,454)
|
|
Available-for-sale
BioTime securities contributed by BioTime
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
34,985,163
|
|
Cancellation of
indebtedness to BioTime
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
5,000,000
|
|
Transaction costs
paid by BioTime, on behalf of the Company
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
300,000
|
|
Intangible assets
acquired from Geron
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
29,017,009
|
|
Deferred tax
liability arising from difference in book versus tax basis on Geron
intangible assets acquired
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
11,558,243
|
|
Investment in
affiliates, contributed by BioTime
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
415,543
|
|
Common stock and
common stock warrants issued to BioTime and Geron in connection
with acquisition and transfer of assets
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
74,098,333
|
|
Common stock issued
upon investment by BioTime
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
50,000
|
|
Reduction of
subscription receivable
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
(50,000)
|
|
Common stock issued
in exchange for non-cash consideration in connection with
investment by officer
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
1,740
|
|
SOURCE Asterias Biotherapeutics, Inc.